<ul>
<li>Savara presented long-term efficacy and safety results at the American Thoracic Society International Conference 2026 from the ongoing Phase 3 IMPALA-2 open-label extension of inhaled molgramostim in autoimmune pulmonary alveolar proteinosis.     *      The update showed sustained improvement in lung function and respiratory quality of life in patients who stayed on molgramostim, supporting durability of benefit with longer exposure.     *      Patients who switched from placebo to molgramostim in the open-label period also improved on the same measures, narrowing the gap versus earlier-treated patients.     *      The safety profile remained broadly consistent with earlier trial data, with no treatment-related adverse events leading to study discontinuation.     *      IMPALA-2 enrolled 164 patients, with 160 completing the double-blind period and all 160 entering the open-label extension, a retention signal that could support the program’s regulatory and commercial positioning. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605191415BIZWIRE_USPR_____20260519_BW029544) on May 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</li>
</ul>

SVRA

LABU

SBIO

<p>Savara presented 48-week data from the Phase 3 IMPALA-2 trial at the ATS International Conference 2026, showing long-term efficacy and safety of molgramostim in aPAP. Results indicated sustained lung function improvement and quality of life in patients on molgramostim, with those switching from placebo also showing benefits. The safety profile was consistent with previous trials, and 160 out of 164 enrolled patients completed the study, indicating strong retention.</p>

Savara reports 48-week open-label IMPALA-2 data for molgramostim in aPAP